New COVID-19 vaccine shows promise in early trial

NCT ID NCT04639466

Completed ⭐️ VACCINE ⭐️ Sponsor: GeoVax, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a new COVID-19 vaccine called GEO-CM04S1 in 119 healthy adults. The vaccine uses a modified virus to teach the body to fight SARS-CoV-2. Researchers checked for side effects and measured antibody levels to see if the vaccine works. The trial is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GEO-CM04S1 (a synthetic MVA-based SARS-CoV-2 vaccine)
What this could lead to: If successful, this vaccine could provide a new option to prevent COVID-19 infection and boost immunity against the virus.
What could go wrong: This is an early-phase trial with only 119 participants, so results may not apply to the general population. The vaccine may not produce strong enough immunity or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 INFECTION

Contacts and locations

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
EmVenio Research

Claremont, California, 91711, United States
Millennium Clinical Trials

Thousand Oaks, California, 91360, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.